Neuroacanthocytosis in China: A Review of Published Reports

Jia Liu, Benedikt Bader & Adrian Danek*
Neurologische Klinik, Klinikum der Universität München, 81377 München, Germany

Abstract

Background: Neuroacanthocytosis (NA) syndromes are a group of rare diseases characterized by the presence of acanthocytes and neuronal multisystem pathology, including chorea-acanthocytosis (ChAc), McLeod syndrome (MLS), Huntington’s disease-like 2 (HDL-2), and pantothenate kinase-associated neurodegeneration (PKAN). China has the largest population in the world, which makes it a good location for investigating rare diseases like NA.

Methods: We searched Medline, ISI Proceedings, China National Knowledge Infrastructure, and Wanfang Data for literature published through December 31, 2013 for all the published Chinese NA case reports and extracted the clinical and laboratory findings.

Results: A total of 42 studies describing 66 cases were found to be eligible for inclusion. Age of symptom onset ranged from 5 to 74 years. The most common findings included hyperkinetic movements (88%), orofacial dyskinesia (80%), dystonia (67%), and dysarthria (68%), as well as caudate atrophy or enlarged lateral ventricles on neuroimaging (64%), and elevated creatine kinase (52%). Most cases were not confirmed by any specific molecular tests. Only two cases were genetically studied and diagnosed as ChAc or MLS.

Discussion: In view of the prevalence of NA syndromes in other countries, the number of patients in China appears to be underestimated. Chinese NA patients may benefit from the establishment of networks that offer specific diagnoses and care for rare diseases.

Keywords: Neuroacanthocytosis, chorea-acanthocytosis, McLeod syndrome, neurodegeneration with brain iron accumulation, China

Citation: Liu J, Bader B, Danek A. Neuroacanthocytosis in China: a review of published reports. Tremor Other Hyperkinet Mov. 2014; 4. doi: 10.7916/D8Q23XDX

* To whom correspondence should be addressed. E-mail: danek@lmu.de

Editor: Elan D. Louis, Columbia University, USA
Received: May 6, 2014 Accepted: July 21, 2014 Published: October 31, 2014

Copyright: © 2014 Liu et al. This is an open-access article distributed under the terms of the Creative Commons Attribution–Noncommercial–No Derivatives License, which permits the user to copy, distribute, and transmit the work provided that the original author(s) and source are credited; that no commercial use is made of the work; and that the work is not altered or transformed.

Funding: None.
Financial Disclosures: None.
Conflict of Interest: The authors report no conflict of interest.

Introduction

Neuroacanthocytosis (NA), an umbrella term for a group of rare diseases characterized by misshapen erythrocytes (acanthocytes) and neuronal multisystem pathology, includes diseases such as autosomal recessive chorea-acanthocytosis (ChAc), X-linked McLeod syndrome (MLS), Huntington’s disease-like 2 (HDL-2), and pantothenate kinase-associated neurodegeneration (PKAN).1 NA was first described as Levine-Critchley syndrome on the basis of reports by Levine and Critchley in two families from North America in the 1960s.2,3 Although the clinical manifestations of NA resemble Huntington’s disease (HD), there are clear differences in the mode of inheritance and neuropathological changes. In the last decade, molecular and protein methods have rapidly developed for the diagnosis of different NA subtypes.

China has the largest population in the world (1.35 billion), making it a suitable location for investigating rare diseases like NA. The first Chinese NA literature is a translation of the paper by Sakai et al in 1981.4,5 Over the last 30 years, few Chinese NA case reports have been published.6–53 Moreover, communication with foreign scholars was limited because most of the reports were published in Chinese. ChAc has been reported in many different ethnic groups, and the relatively high prevalence in Japan appears to be due to a founder mutation.54 In light of the similar East Asian backgrounds in the two countries, we suspect that in China NA syndromes are underdiagnosed, leading to a significant underestimation of the prevalence.

In the current study, we systematically reviewed Chinese NA epidemiology by searching for published NA cases. We aimed to
Table 1. Baseline Information on NA Cases from China

| Ref. | Place of Diagnosis | Year of Publication | No. Cases | Sex | AOO | Initial Symptoms | Acanthocytes (%) | Reported Diagnosis | Our Diagnostic Hypothesis |
|------|--------------------|---------------------|-----------|-----|-----|------------------|------------------|---------------------|-------------------------|
| 6    | Anhui              | 1984                | 2         | 2M  | 19, 27 | Orof. (1), MD/Orof. (1) | 23%, 3% | ChAc               |
| 7    | Anhui              | 1987                | 2         | 2M  | 26, 32 | DYA (1), MD/Orof. (1) | 10%     | ChAc               |
| 8    | Anhui              | 2000                | 2         | 2F  | 45, 46 | MD (1), PSY (1) | 35%, 17% | ChAc               |
| 9    | Anhui              | 2004                | 1         | 1M  | 39     | Orof./MD         | 4–7%    | ChAc               |
| 10   | Beijing            | 2005                | 1         | 1F  | n.a.   | MD               | 4%      | ChAc               |
| 11–14| Beijing            | 2005, 2012          | 8         | 2M, 6F | 10–35 | Orof. (4), MD (3), PN (1) | >10% | NA                 |
| 15   | Beijing            | 2007                | 2         | 2M  | 27, 37 | MD (1), EPI (1) | 15–25% | ChAc               |
| 16   | Beijing            | 2010                | 1         | 1M  | 11     | n.a.             | 30%    | NA                 |
| 17, 18| Beijing            | 2013                | 1         | 1M  | 42     | MD/Orof.        | >40%    | NA NBIA            |
| 19   | Beijing            | 2013                | 3         | 3M  | 16–43  | MD, Orof. (2), BP (1) | >30% | NA                 |
| 20   | Chongqing          | 2013                | 1         | 1F  | 33     | DYA/WI/MD/Orof. | >3%     | ChAc               |
| 21   | Gansu              | 2009                | 1         | 1M  | 20     | MD               | n.a.    | NA                 |
| 22   | Guangdong          | 2003                | 1         | 1M  | 42     | Orof.            | 30%    | ChAc               |
| 23   | Heilongjiang       | 1989                | 1         | 1F  | 36     | DYA/Orof.       | 15–20% | ChAc               |
| 24   | Heilongjiang       | 1989                | 2         | 1M, 1F | 9, 11 | Orof.            | 56%, 28% | ChAc NBIA         |
| 25   | Heilongjiang       | 1990                | 1         | 1F  | 38     | Orof.            | 40–50% | ChAc               |
| 26, 27| Heilongjiang       | 2003, 2007          | 1         | 1F  | 35     | Orof.            | 28.5%  | ChAc               |
| 28   | He’nan             | 2005                | 1         | 1F  | 30     | Orof./EPI       | 25%    | NA                 |
| 29   | He’nan             | 2011                | 2         | 1M, 1F | 30, 31 | MD (1), Orof. (1) | 35%, 25% | ChAc               |
| 30   | He’nan             | 2012                | 1         | 1M  | 43     | MD               | 11%–15% | ChAc               |
| 31   | Hong Kong          | 2013                | 1         | 1M  | 47     | GD/MD           | 16%    | MLS*               |
| 32   | Hubei              | 2007                | 1         | 1F  | 28     | Orof.           | 6–8%   | NA                 |
| 33   | Hubei              | 2013                | 1         | 1M  | 37     | n.a.            | n.a.   | NA                 |
| 34   | Hu’nan             | 2013                | 1         | 1F  | 24     | n.a.            | n.a.   | ChAc*              |
| 35   | Jiangsu            | 2012                | 1         | 1F  | 20     | MD/Orof.        | 7.8%   | ChAc               |
| 36   | Liaoning           | 1989                | 1         | 1M  | 28     | Orof.           | 84%    | ChAc               |
summarize the features of Chinese NA cases in comparison with other countries and identify potential reasons for underestimation.

**Methods**

We searched Medline (from January 1, 1949 to December 31, 2013), ISI Proceedings (January 1, 1990 to December 31, 2013), China National Knowledge Infrastructure (http://www.cnki.net, from January 1, 1979 to December 31, 2013) and Wanfang Data (http://www.wanfangdata.com.cn, from January 1, 1984 to December 31, 2013). The search terms in English and their Chinese equivalents included “neuroacanthocytosis,” “chorea-acanthocytosis,” “McLeod syndrome,” “choreoacanthocytosis,” “hereditary acanthocytosis syndrome,” and “Levine-Critchley syndrome.” We also tried to identify cases from cross-references between papers. We only included those case reports where an explicit diagnosis of NA had been made by the original authors. For inclusion, patients had to be of Chinese origin and diagnosed in China. We extracted information on geographical origin, sex, age of onset, and clinical and laboratory findings from each case.

**Results**

We identified a total of 48 publications with 66 cases reported (37 males and 29 females) (Table 1). All of these patients had been diagnosed with NA, ChAc, or MLS by the reporting physicians. Only one ChAc case was confirmed by a genetic test (VPS13A gene), and no cases were confirmed by Western blot for the protein chorein that is affected in ChAc. An elevated proportion of acanthocytes in blood samples was regarded as the most important diagnostic clue by Chinese physicians. However, heterogeneous methods for detecting

| Ref. | Place of Diagnosis | Year of Publication | No. Cases | Sex | AOO | Initial Symptoms | Acanthocytes (%) | Reported Diagnosis | Our Diagnostic Hypothesis |
|------|-------------------|---------------------|-----------|-----|-----|------------------|------------------|--------------------|------------------------|
| 37   | Neimenggu         | 2005                | 1         | 1M  | 32  | EPI              | 10%              | ChAc               |                        |
| 38   | Neimenggu         | 2007                | 1         | 1M  | 34  | MD               | 10%              | ChAc               |                        |
| 39   | Neimenggu         | 2012                | 1         | 1M  | 38  | Orof.            | 5%               | ChAc               |                        |
| 40   | Qinghai           | 2006                | 1         | 1F  | 24  | MD               | 18%              | NA                 |                        |
| 41   | Shandong          | 2001                | 3         | 3F  | 20–21 | MD             | 12%              | NA                 |                        |
| 42   | Shandong          | 2013                | 1         | 1M  | 32  | MD/Orof.         | 10%              | ChAc               |                        |
| 43   | Shandong          | 2013                | 3         | 2M, 1F | 26–50 | MD/Orof. (1), PSY (2) | >30%             | ChAc               |                        |
| 44   | Shanghai          | 2008                | 1         | 1F  | 33  | MD/Orof.         | 7–8%             | ChAc               |                        |
| 45   | Shanghai          | 2008                | 1         | 1M  | 5   | DYT              | >30%             | NA                 | NBIA                  |
| 46   | Shanghai          | 2010                | 1         | 1F  | 55  | WI               | >20%             | NA                 |                        |
| 47   | Shanghai          | 2012                | 3         | 2M, 1F | 31–74 | MD (1), GD (2) | 10–28%           | NA                 |                        |
| 48   | Shanghai          | 2013                | 1         | 1M  | 46  | WI, DYA          | 44.9%            | NA                 |                        |
| 49, 50 | Shanxi          | 2004, 2012          | 3         | 2M, 1F | 26–30 | EPI (2), Orof. (1) | 12–30%           | ChAc               |                        |
| 51   | Sichuan           | 2012                | 2         | 2M  | 17, 18 | Orof. (2)   | 6%, 6%           | ChAc               |                        |
| 52   | Sichuan           | 1988                | 1         | 1M  | 25  | Orof.            | 4%               | ChAc               |                        |
| 53   | Taiwan            | 2006                | 1         | 1F  | 31  | MD               | 49%              | NA                 |                        |

Abbreviations: *, Gene Confirmed; AOO, Age of Onset; BP, Blepharospasm; ChAc, Chorea-Acanthocytosis; DYA, Dysarthria; DYT, Dystonia; EPI, Epilepsy; F, Female; GD, Gait Disturbance; M, Male; MD, Movement Disorders (Chorea or Hyperkinetic Movements); MLS, McLeod Syndrome; n.a., Not Available; NA, Neuroacanthocytosis; NBIA, Neurodegeneration with Brain Iron Accumulation (Type I/Type II); No., Number; Orof., Orofacial Dyskinesia; PN, Parkinsonism; PSY, Psychiatric Symptoms; Ref., Reference; WI, Walking Instability.
acanthocytosis were used in the different reports, thus affecting the accuracy of the test. Only one MLS case, from Hong Kong, was reported with a corresponding XK gene mutation.

In the most recent decade (2004 to 2013) the number of reported cases increased dramatically, being about five times the number documented from 1984 to 1993, and seven times the number documented between 1994 and 2003 (Figure 1). No video recordings were published with the publications reviewed in this study. With respect to the geographic distribution, all cases originated from 19 Chinese provinces, with 16 cases reported in Beijing, 7 cases from Anhui, and 7 cases from Shandong as the top 3 provinces. The ages of onset ranged from 5 to 74 years and were concentrated in the third and fourth decades ($n = 37, 56\%$) (Figure 2). Common initial symptoms were orofacial dyskinesia ($n = 27, 41\%$) and hyperkinetic limb or trunk movements ($n = 27, 41\%$). Dysarthria, epilepsy, gait disturbance, parkinsonism, and psychiatric symptoms were also reported as the initial symptoms. Diagnoses were mainly made based on the presence of a hyperkinetic movement disorder, elevated acanthocytes in the blood, the pattern of inheritance (recessive), and the exclusion of other possible diseases, such as HD.

Figure 3 summarizes the clinical and laboratory findings reported in Chinese NA cases. The most frequent findings were hyperkinetic movements ($n = 58, 88\%$). Orofacial dyskinesia was reported in 53 patients (80\%). In addition, dystonia ($n = 44, 67\%$) and dysarthria ($n = 45, 68\%$) were also common. 10 patients (15\%) suffered from epilepsy, and 22 patients (33\%) exhibited psychiatric symptoms.

With respect to clinical investigations, caudate atrophy or enlarged lateral ventricles on neuroimaging ($n = 42, 64\%$) and elevated CK ($n = 34, 52\%$) were the most frequently reported.

### Discussion

Hyperkinetic movements and orofacial dyskinesia were the most common symptoms in this series of Chinese NA cases, reported in 88\% and 80\% of patients, respectively. This is consistent with the literature in that orofacial dyskinesia appears to be a relatively specific NA symptom, characterized by tongue protrusion and feeding dystonia. Chorea was typical in the early stages and tended to progress to parkinsonism. Parkinsonism has occasionally been reported to be the initial symptom.56,57

We found lower proportions of patients with epilepsy (15\%) and psychiatric symptoms (33\%) than reported in the literature (50\% and 66\%, respectively).58,59

In our study, 52\% of Chinese NA cases had elevated CK levels, while only 11\% of cases exhibited liver enzyme elevation, suggesting that CK is probably a more useful biomarker for NA than acanthocytes or liver enzymes, as is consistent with the literature. However, values within normal ranges are likely to have been omitted in many publications, thus, we could not accurately calculate the proportion of patients with normal CK or liver enzyme levels.58

The number of cases reported for 1994–2003 is relatively low in comparison to the numbers for 1984–1993 and 2004–2013. It is possible that some cases were not reported because they were not recognized or were not thought to be of interest after awareness was originally raised regarding the syndrome. It is important to determine whether these low rates of reported cases are due to publication bias and incomplete documentation, or whether these discrepancies are due to ethnic differences.

The clinical diagnosis of NA in China is mainly based on clinical manifestations and an elevated proportion of acanthocytes in the
blood, as well as the exclusion of other possible diseases. Previously this was the standard diagnostic evaluation worldwide (e.g., a Chinese patient diagnosed with ChAc in Singapore in the 1980s). Recently, however, there have been clear NA cases without acanthocyte elevation. The other forms of NA, such as HDL-2 and PKAN, have not yet been reported in China. However, as some of the NA cases reported had an early age of onset (Table 1), it is likely that PKAN was the correct diagnosis.

With regard to MLS, only one Chinese case has been identified, indicating that it is probably under-diagnosed. Without specific molecular testing, an accurate diagnosis for presumed NA cases is impossible. As an alternative to DNA analyses, chorein detection by Western blot is an inexpensive method for diagnosing ChAc, and Kell antigen phenotyping can be performed to diagnose MLS.

In view of the prevalence of NA syndromes in countries such as the United Kingdom and Germany (approximately 3 in 10 million), the number of NA patients in China should be at least 400 and appears to be underestimated. In addition to raising awareness among Chinese neurologists, the absence of specific molecular tests is the main diagnostic flaw that needs to be addressed. A Chinese network of NA collaboration may improve the diagnosis and treatment for patients affected by this group of incapacitating hyperkinetic movements.

References

1. Walker RH, Jung HH, Danek A. Neuroacanthocytosis. Handb Clin Neurol 2011;100:141–151.
2. Levine IM, Estes JW, Looney JM. Hereditary neurological disease with acanthocytosis. A new syndrome. Arch Neurol 1968;19:403–409.
3. Critchley EM, Clark DB, Wilder A. An adult form of acanthocytosis. Trans Am Neurol Assoc 1967;92:132–137.
4. Zhou XF. Choreoacanthocytosis. Clues to clinical diagnosis (in Chinese). Chin J Neurol 2005;21:54–55.
5. Sakai T, Mawatari S, Iwashita H, Goto I, Kuroiwa Y. Chorea-acanthocytosis. Clues to clinical diagnosis. Arch Neurol 1981;38:335–338.
6. Yang RM, Bao YZ, Chen WD. Two cases of chorea-acanthocytosis (in Chinese). New Chinese Medicine 1984;15:28–29.
7. Yang RM, Chen WD, Lou ZP. A family of chorea-acanthocytosis (in Chinese). Chin J Neurol Sci 1987;5:311–312.
8. Sun HT. Two cases of chorea-acanthocytosis (in Chinese). Chin J Neurol 2000;33:134.
9. Yang RM, Yu XE, Li K, HouHX. One case of chorea-acanthocytosis and review (in Chinese). Chin J Neurol Sci 2004;12:290–293.
10. Bo L, Li YM, Liu FH. Care for one case of chorea-acanthocytosis (in Chinese). Chin J Prac Nurs 2005;21:54–55.
11. Zhou XQ, Guo HZ, Shi XS, et al. Clinical, laboratory and neuroimaging characteristics of neuroacanthocytosis (in Chinese). Chin J Neurol 2012;45:112–115.
12. Zhou LX, Guan HZ, Ni J, Wan XH, Chen L, Cui LY. Progressive involuntary movements in mouth tongue and limbs (in Chinese). Chin J Contemp Neurol Neurosurg 2011;11:117–120.
13. Liu CY, Gao J, Yang YC, Cui LY, Wan XH, Ge CW. Choreoacanthocytosis (in Chinese). Chin J Contemp Neurol Neurosurg 2005;5:175–178.
14. Wei YP, Wan XH, Gao J, et al. Clinical and neuropathological study of three neuroacanthocytosis cases (in Chinese). Chin J Neurol 2005;38:712–713.
15. Zhou H, Zhang XH, Sun YL. Report of two chorea-acanthocytosis cases (in Chinese). Chin J Neuroimmun Neurol 2007;14:297–299.
16. Hu YH, Wang HJ, Dong S. Perioperative nursing of a patient with neuroacanthocytosis (in Chinese). Chin J Nurs 2010;45:413–415.
17. Zhao XP, Tang LY, Chen F, Wei YZ, Yin WM, Zhang WW. One case report of neuroacanthocytosis (in Chinese). Beijing Med J 2013;35:407–408.
18. Wu HW. Experience of clinical nursing for one case of chorea-acanthocytosis (in Chinese). Modern Journal of Integrated Traditional Chinese and Western Medicine 2013;22:668–669.
19. Xu EH, Xue XF, Wang XL, Xuan XQ, Jia JP. Clinical investigation of neuroacanthocytosis with the report of three cases (in Chinese). Chin J Intern Med 2013;52:760–762.
20. Xie SJ, Hu J, Chen KN, Shi SG. One case of chorea-acanthocytosis (in Chinese). J Third Mil Med Univ 2013;35:2045,2050.
21. Tang X. One case of neuroacanthocytosis (in Chinese). Chin Gen Pract 2009;12:2062.
22. Zhang WX, Li JR, Yang SL, Zhang XZ, An YH, Chen HZ. Case report of chorea-acanthocytosis (in Chinese). Chin J Neurol 2003;36:331.
23. Zheng BR, Han H, Qi ZZ, Wang DS. A case report of chorea-acanthocytosis (in Chinese). Harbin Medical University Bulletin 1989;23:126–127.
24. Zhang JB, Gong LM, Dai JC, Han H. Two case-reports of chorea-acanthocytosis (in Chinese). Harbin Medical University Bulletin 1989;23:283.
25. Yang AY, Liang YQ. One case report of chorea-acanthocytosis (in Chinese). Medic J Indust Enterpr 1990;1:48.
26. Qu SB, Liu LR, Sheng L, Li GL. One case of Chorea-acanthocytosis (in Chinese). Chin J Med Genet 2003;20:176.
27. Qu SB, Liu LR, Sheng L, Li GL. Chorea-acanthocytosis presenting with elevated prolactin. Case report. BJM 2007;6:1–5.
28. Wang ZM, Cao YY. One case of neuroacanthocytosis, misdiagnosed as obsessive compulsive disorder (in Chinese). Chin J Psychiatry 2005;38:26.
29. Zhang AL, Zhao XY. Chorea-acanthocytosis: a clinical report of two cases (in Chinese). Chin J Neurol Med 2011;10:75–75.
30. Ma CM, Han YZ, Wang HL. One case report of chorea-acanthocytosis (in Chinese). Chin J Prac Neurol Dis 2012;15:96.
31. Man BL, Yuen YP, Yip SF, Ng SH. The first case report of McLeod syndrome in a Chinese patient. BMJ Case Rep 2013;pii:3br2013200205.
32. Zhao H, Mao SP. One case report of neuroacanthocytosis (in Chinese). Stroke Neurol Dis 2007;14:318–319.
33. Long X, Xiong N, Zhu Q, et al. The combination of SPECT-CT and functional MR imaging in the diagnosis of neuroacanthocytosis (abstract). Med Diagn 2013;28 Suppl 1:715.
34. Chen Z, Wang JL, Tang BS, et al. Using next-generation sequencing as a genetic diagnostic tool in rare autosomal recessive neurologic Mendelian disorders. Neurobiol Aging 2013;34:2442.e11–7.
35. Zhao H, Wang G, Niu FX. One case of chorea-acanthocytosis and review (in Chinese). Chin J Diffic and Compl Med J 2012;11:63–64.
36. Dong GF, Bao LP, Jin N, Gong ZL, Lei ZL. One case of chorea-acanthocytosis (in Chinese). Chin J Prac Int Med 1989;9:310.
37. Luo YC, Zhao B. Epilepsy-onset in chorea-acanthocytosis (in Chinese). *Brain Neurol Dis J* 2005;13:449.
38. Sa ru la B, Yuan J, Zhu RX. One case of chorea-acanthocytosis (in Chinese). *Inner Mongolia Med J* 2007;39:1010.
39. Jia RP, Zhao XY, Xu N, Bai XH, Zhang IJ. One case of chorea-acanthocytosis syndrome and literature review (in Chinese). *Clinical Focus* 2012;27:1913–1914.
40. Zeng GX. One case of neuroacanthocytosis and review (in Chinese). *Chin J Diffic and Compl Cas* 2006;5:220.
41. Liu SP, Li DN, Wang SZ, et al. Familial neuroacanthocytosis (in Chinese). *Chin J Neurol* 2001;34:16–18.
42. Luan HH, Liu YM, Zhang JY, Chen L, Li JH, Zhang XG. Clinical features of chorea-acanthocytosis complicated with chronic active hepatitis (report of one case) (in Chinese). *J Clin Neurol* 2013;26:372–374.
43. Shan PY, Meng YY, Yu XL, Liu SP, Li DN. Cognitive disorders and neuropsychiatric behaviors in chorea-acanthocytosis (in Chinese). *Chin J Neurol* 2013;46:769–772.
44. Chen W, Wang WA, Liu ZG. One case of chorea-acanthocytosis and review (in Chinese). *Chin J Prac Int Med* 2008;28:890–891.
45. Jiang YP, Zhou Y. Case discussion of generalized dystonia in children (in Chinese). *Chin Clin Neurol* 2008;16:562–564.
46. Jiang YP. Case discussion of late-onset cerebellar ataxia (in Chinese). *Chin Clin Neurol* 2010;18:223–224.
47. Zhang QY, Wang YG, Jiang YP, et al. Ataxia-neuroacanthocytosis (3 cases report) (in Chinese). *Chin Clin Neurol* 2012;20:18–23.
48. Ling L. Cerebellar ataxia in a case of neuroacanthocytosis (in Chinese). *Journal of Sichuan of Traditional Chinese Medicine* 2013;31:82–83.
49. Cui AQ, Li YB, Liu XX, Chen YP, Li DR, Xu JL. Three cases in a family of hereditary chorea-acanthocytosis (in Chinese). *Chin J Med Genet* 2004;5:421.
50. Cui AQ, Li YB, Liu SP, Chen YP, Li DR, Xu JL. Hereditary chorea-acanthocytosis (in Chinese). *Journal of Shansi Medical University* 2005;36:93–95.
51. Li P, Huang R, Song W, et al. Deep brain stimulation of the globus pallidus internal improves symptoms of chorea-acanthocytosis. *Neuro Sci* 2012;33:269–274.
52. He SL, Zhang Y. One case of chorea-acanthocytosis (in Chinese). *Chin J Postgrad Med* 1988;11:26.
53. Liu FC, Wei LJ, Shih PY. Effect of levitiracetam on truncal tic in neuroacanthocytosis. *Acta Neurol Taiwan* 2006;15:38–42.
54. Jung HH, Danek A, Walker RH. Neuroacanthocytosis syndromes. *Orphanet J Rare Dis* 2011;6:68.
55. Dobson-Stone C, Velayos-Baeza A, Filippone LA, et al. Chorine detection for the diagnosis of chorea-acanthocytosis. *Ann Neurol* 2004;56:299–302.
56. Bostantjopoulou S, Katsarou Z, Kazis A, Vadikolia C. Neuroacanthocytosis presenting as parkinsonism. *Mov Disord* 2000;15:1271–1273.
57. Bader B, Walker RH, Vogel M, Prosielg M, McIntosh J, Danek A. Tongue protrusion and feeding dystonia: a hallmark of chorea-acanthocytosis. *Mov Disord* 2010;25:127–129.
58. Bader B, Danek A, Walker RH. Chorea-acanthocytosis. In: Walker RH, ed. The differential diagnosis of chorea. New York: Oxford University Press;2011;122–148.
59. Scheid R, Bader B, Ott DV, Morkenschlager A, Danek A. Development of mesial temporal lobe epilepsy in chorea-acanthocytosis. *Neurology* 2009;73:1419–1422.
60. Ong B, Devathasan G, Chong PN. Choreoacanthocytosis in a Chinese patient: a case report. *Singapore Med J* 1989;30:506–508.
61. Bayreuther C, Berg M, Ferrero-Vacher C, Chauessenot A, Lebrun C. Choreoacanthocytosis without acanthocytes (in French). *Rev Neurol (Paris)* 2010;166:100–103.
62. Danek A, Rubio JP, Rampoldi L, et al. McLeod neuroacanthocytosis: genotype and phenotype. *Ann Neurol* 2001;50:755–764.

**Note:**

Since the acceptance of this article, additional NA cases from China were reported:

Man BL, Yuen YP, Fu YP. The first report of a Chinese family with McLeod syndrome. BMJ case reports. 2014. doi:10.1136/bcr-2013-202785

Long X, Xiong N, Guo K, et al. Functional neuroimaging might enable the early diagnosis of neuroacanthocytosis. Can J Neurol Sci. 2014;41:402-404